CXCL12 mRNA expression as an independent marker of liver fibrogenesis in rats
https://doi.org/10.55959/MSU0137-0952-16-2022-77-4-248-257
Abstract
The accumulated knowledge about the role of the CXCL12 chemokine in the initiation and development of liver fibrosis is insignificant and does not allow us to assess the potential of using the CXCL12 mRNA level as an independent marker of fibrogenesis and processes associated with fibrosis and cirrhosis. Thioacetamide modeling of liver fibrosis and cirrhosis in male Wistar rats showed a low level of CXCL12 mRNA expression (p = 0.0000) at all stages of fibrosis progression. At the beginning of the experiment (3 weeks), a decrease in the level of CXCL12 mRNA by 2.93 times (p = 0.0000) compared with the control group was revealed. After 3, 7 and 9 weeks, the level of gene expression decreased gradually (p = 0.0000). During the reorganization of the parenchyma of the organ and the formation of false hepatic nodules (11, 13 and 15 weeks), a certain stabilization of the level of gene expression was noted. Against the background of the total formation of pseudohepatic nodules and a pronounced diffuse proliferation of connective tissue (17 weeks), the level of CXCL12 mRNA expression increased, but did not reach the level of control values. Based on our results, the level of CXCL12 mRNA is associated with the processes of fibrosis/cirrhosis and can act as an independent marker of fibrogenesis, but not cirrhosis of the liver against the background of toxic damage to it by thioacetamide. When conducting fundamental and preclinical studies to evaluate the effectiveness of drugs using this experimental model, the minimum allowable number of control points is considered to be three, namely: portal fibrosis (3 weeks), bridging fibrosis (5 weeks), the beginning of the process of transformation of liver fibrosis into cirrhosis (9 weeks).
Keywords
liver fibrosis and liver cirrhosis,
thioacetamide intoxication,
real-time polymerase chain reaction,
CXCL12 mRNA expression level,
scale K.G. Ishak
Supporting agencies: The work was carried out within the framework of the state research program “Fundamental and Applied Sciences for Medicine” of the Ministry of Health of the Republic of Belarus, task 2.89
About the Authors
E. I. Lebedeva
Vitebsk State Order of Peoples’ Friendship Medical University
Belarus
Belarus
27 Frunze Ave., 210009, Vitebsk
A. S. Babenka
Belarussian State Medical University
Belarus
Belarus
83–15 Dzerzhinsky ave., 220116, Minsk
A. T. Shchastny
Vitebsk State Order of Peoples’ Friendship Medical University
Belarus
Belarus
27 Frunze Ave., 210009, Vitebsk
References
1. Zhou W., Guo S., Liu M., Burow M.E., Wang G. Targeting CXCL12/CXCR4 axis in tumor immunotherapy // Curr. Med. Chem. 2019. Vol. 26. N 17. P. 3026–3041.
2. Dewan M.Z., Ahmed S., Iwasaki Y., Ohba K., Toi M., Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer // Biomed. Pharmacother. 2006. Vol. 60. N 6. P. 273–276.
3. Khare T., Bissonnette M., Khare S. CXCL12- CXCR4/CXCR7 axis in colorectal cancer: Therapeutic target in preclinical and clinical studies // Int. J. Mol. Sci. 2021. Vol. 22. N 14: 7371.
4. Ray P., Stacer A.C., Fenner J., Cavnar S.P., Meguiar K., Brown M., Luker K.E., Luker G.D. CXCL12-γ in primary tumors drives breast cancer metastasis // Oncogene. 2015. Vol. 34. N 16. P. 2043–2051.
5. Qin L., Qin J., Zhen X., Yang Q., Huang L. Curcumin protects against hepatic stellate cells activation and migration by inhibiting the CXCL12/CXCR4 biological axis in liver fibrosis: A study in vitro and in vivo // Biomed. Pharmacother. 2018. Vol. 101. P. 599–607.
6. Cui L.N., Zheng X.H., Yu J.H., Han Y. Role of CXCL12-CXCR4/CXCR7 signal axis in liver regeneration and liver fibrosis // Zhonghua Gan Zang Bing Za Zhi. 2021. Vol. 29. N 9. P. 900–903.
7. Chiraunyanann T., Changsri K., Sretapunya W., Yuenyongchaiwat K., Akekawatchai C. CXCL12 G801A polymorphism is associated with significant liver fibrosis in HIV-infected Thais: a cross-sectional study // Asian Pac. J. Allergy Immunol. 2019. Vol. 37. N 3. P. 162–170.
8. Janowski M. Functional diversity of SDF-1 splicing variants // Cell Adh. Migr. 2009. Vol. 3. N 3. P. 243–249.
9. Korbecki J., Kojder K., Kapczuk P., Kupnicka P., Gawrońska-Szklarz B., Gutowska I., Chlubek D., Baranowska-Bosiacka I. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors – A review of literature // Int. J. Mol. Sci. 2021. Vol. 22. N 2: 843.
10. Банин В.В., Быков В.Л. (ред.). Международные термины по цитологии и гистологии человека с офици- альным списком русских эквивалентов. М.: ГЭОТАР- Медиа, 2009. 272 с.
11. Guerrier M., Attili F., Alpini G., Glaser S. Prolonged administration of secretin to normal rats increases biliary proliferation and secretin-induced ductal secretory activity // Hepatobiliary Surg. Nutr. 2014. Vol. 3. N 3. Р. 118–125.
12. Everhart J.E., Wright E.C., Goodman Z.D., et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial // Hepatology. 2010. Vol. 51. N 2. P. 585–594.
13. Жижин К.С. Медицинская статистика: Учебное пособие. Ростов-на-Дону: Феникс, 2007. 160 с.
14. Liu Y., Yang X., Jing Y., Zhang S., Zong C., Jiang J., Sun K., Li R., Gao L., Zhao X., Wu D., Shi Y., Han Z., Wei L. Contribution and mobilization of mesenchymal stem cells in a mouse model of carbon tetrachlorideinduced liver fibrosis // Sci. Rep. 2015. Vol. 5. N 2: 17762.
15. King A., Houlihan D.D., Kavanagh D., et al. Sphingosine-1-phosphate prevents egress of hematopoietic stem cells from liver to reduce fibrosis // Gastroenterology. 2017. Vol. 153. N 1. P. 233–248.e16.
16. Muthiah M.D., Huang D.Q., Zhou L., Jumat N. H., Choolani M., Chan J.K.Y., Wee A., Lim S.G., Dan Y.Y. A murine model demonstrating reversal of structural and functional correlates of cirrhosis with progenitor cell transplantation // Sci. Rep. 2019. Vol. 9. N 1: 15446.
17. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments // Clin. Chem. 2009. Vol. 55. N 4. P. 611–622.
18. Watanabe Y., Tsuchiya A., Seino S., Kawata Y., Kojima Y., Ikarashi S., Starkey Lewis P.J., Lu W.Y., Kikuta J., Kawai H., Yamagiwa S., Forbes S.J., Ishii M., Terai S. Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice stem cells // Transl. Med. 2019. Vol. 8. N 3. P. 271–284.
19. Wang J., Sun M., Liu W., Li Y., Li M. Stem cellbased therapies for liver diseases: An overview and update // Tissue Eng. Regen. Med. 2019. Vol. 16. N 2. P. 107–118.
20. Griessmair L., Pirringer L., Mountford S., Sendelhofert A., Makeschin M.C., Koletzko S., Mayr D., Bufler P. Expression of IL-37 correlates with immune cell infiltrate and fibrosis in pediatric autoimmune liver diseases // J. Pediatr. Gastroenterol. Nutr. 2022. Vol. 74. N 11. P. 742–749.
21. Ogawa H., Kaji K., Nishimura N., Takagi H., Ishida K., Takaya H., Kawaratani H., Moriya K., Namisaki T., Akahane T., Yoshiji H. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis // J. Cell. Mol. Med. 2021. Vol. 25. N 8. P. 4001–4013.
22. Cheng Q., Li C., Yang C.F., Zhong Y.J., Wu D., Shi L., Chen L., Li Y.W., Li L. Methyl ferulic acid attenuates liver fibrosis and hepatic stellate cell activation through the TGF-β1/Smad and NOX4/ROS pathways // Chem. Biol. Interact. 2019. Vol. 299. P. 131–139.
23. Wen Y., Lambrecht J., Ju C., Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities // Cell. Mol. Immunol. 2021. Vol. 18. N 1. P. 45–56.
24. Mu M., Zuo S., Wu R.M., Deng K.S., Lu S., Zhu J.J., Zou G.L., Yang J., Cheng M.L., Zhao X.K. Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway // Drug Des. Devel. Ther. 2018. Vol. 12. P. 4107–4115.
25. Xiang D., Zou J., Zhu X., Chen X., Luo J., Kong L., Zhang H. Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling // Phytomedicine. 2020. Vol. 78: 153294.
26. Ni M.M., Wang Y.R., Wu W.W., Xia C.C., Zhang Y.H., Xu J., Xu T., Li J. Novel insights on Notch signaling pathways in liver fibrosis // Eur. J. Pharmacol. 2018. Vol. 826. P. 66–74.
Review
For citations:
Lebedeva E.I., Babenka A.S., Shchastny A.T. CXCL12 mRNA expression as an independent marker of liver fibrogenesis in rats. Vestnik Moskovskogo universiteta. Seriya 16. Biologiya. 2022;77(4):248-257. (In Russ.) https://doi.org/10.55959/MSU0137-0952-16-2022-77-4-248-257
Views:
2858
Email this article 